Search NLS News

People with rare diseases and disabilities face common challenges in the Nordic region. Small populations in each individual country make it tricky to set up treatment protocols and gather data, for example, and Nordic cooperation is being highlighted as a possible answer to many of the issues. It is the rare that unites, and only […]

On May 24th, five Nordic university hospitals signed a Memorandum of Understanding (MoU) to inaugurate the new alliance, The Nordic University Hospital Alliance (NUHA). The goal is to strengthen relationships and collaborations between the hospitals and establish a strategy for addressing healthcare challenges in the Nordic region. The alliance aims to enhance quality and foster […]

Data presented at ASCO from the OPTIMIZE-1 study, of mitazalimab in combination with mFOLFIRINOX chemotherapy, showed that pharmacological analyses identified mitazalimab-induced expansion of CD4 effector T cells one week after first administration as a correlate of treatment outcomes. Alligator Bioscience has announced that two clinical abstracts on its lead drug candidate mitazalimab, a CD40 agonist, […]

NLS asked Nina Rawal, Partner and Co-Head of Ventures at Trill Impact, about her perspective when it comes to financing and supporting rare disease companies. As an investor, what’s your view on rare disease companies and their potential value? “Rare disease is an area that has undergone a minor revolution in recent decades, going from […]

Medivir’s licensee Tango Therapeutics has announced that the phase 1/2 clinical trial of TNG348, a novel USP1 inhibitor, is being terminated due to toxicity observed in the initial study cohorts. TNG348 is a novel USP1 (ubiquitin-specific protease 1) inhibitor, for the treatment of BRCA1/2-mutant and other homologous recombination deficiency (HRD)+ cancers, and has been developed […]

Company creation, metabolic diseases, and AI-powered drug discovery are amongst the hottest trends in 2024. Life science executives have gathered to discuss current matters in the industry several times during this spring, starting with J.P. Morgan’s Annual Healthcare week and followed by Bio-Europe Spring. SwedenBIO was there to connect Swedish life sciences with our international […]

DelSiTech has announced that the company has entered into a licensing agreement with an undisclosed global pharmaceutical company. According to the agreement, DelSiTech grants an exclusive global license to DelSiTech’s Silica Matrix based, controlled release technology for development and commercialization of an undisclosed long-acting injectable drug product. Under the terms of the agreement, the licensee […]

It used to be canon that to work in drug development, one must be a scientist of some kind. In the last couple of decades we, as an industry, learned that this was true no longer. The average drug development Subject Matter Expert (SME), regardless of scientific training, had to become almost so technically savvy as […]

Alligator Bioscience’s has announced that Shanghai Henlius Biotech has received Investigational New Drug (IND) clearance from the FDA to initiate a Phase 3 study to evaluate HLX22 in combination with trastuzumab and chemotherapy in 1st line HER2-positive advanced gastric cancer patients. HLX22 (AC101) is a monoclonal anti-HER2-antibody, which was out-licensed by Alligator to the South […]

The Board of Directors of Immunovia has resolved to carry out an issue of shares and warrants with preferential rights for the company’s existing shareholders of initially approximately SEK 70 million. The company has received subscription undertakings amounting to a total of approximately SEK 1.3 million, corresponding to approximately 2 percent of the Rights Issue. […]